Jazz Pharma launches once-a-daily Luvox CR

Luvox CR was recently approved by the FDA for the treatment of social anxiety disorder (SAD) and obsessive compulsive disorder (OCD) in adult patients. SAD and OCD are two difficult-to-treat, underdiagnosed and undertreated anxiety disorders.

The company’s sales team has already began communicating with office-based psychiatrists and select primary care physicians about the unique attributes of Luvox CR. These sales professionals will provide samples of Luvox CR in 100mg and 150mg dose strengths that physicians may choose to distribute to their patients.

Samuel Saks, CEO of Jazz, said: “The availability of Luvox CR provides physicians with a new and effective treatment option for the millions of adults in the US suffering from SAD and OCD. Through our educational efforts, we hope to provide physicians and their patients with important information about SAD and OCD.”